Alphabet Inc. bought a new stake in shares of Metsera Inc. (NASDAQ:MTSR - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 4,961,744 shares of the company's stock, valued at approximately $135,059,000. Metsera accounts for about 8.6% of Alphabet Inc.'s investment portfolio, making the stock its 5th biggest position. Alphabet Inc. owned approximately 4.72% of Metsera at the end of the most recent quarter.
Separately, Bank of New York Mellon Corp bought a new position in Metsera during the 1st quarter worth about $884,000.
Metsera Stock Up 1.2%
Shares of Metsera stock traded up $0.51 during midday trading on Tuesday, hitting $42.98. The company had a trading volume of 962,800 shares, compared to its average volume of 808,257. The business has a fifty day moving average price of $29.31. Metsera Inc. has a 12-month low of $12.30 and a 12-month high of $46.43.
Metsera (NASDAQ:MTSR - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($1.03) EPS for the quarter.
Analyst Ratings Changes
Several brokerages have issued reports on MTSR. Wells Fargo & Company started coverage on shares of Metsera in a report on Friday, June 20th. They set an "overweight" rating and a $65.00 target price on the stock. Guggenheim increased their price target on shares of Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research report on Tuesday, June 10th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $55.00.
Check Out Our Latest Research Report on MTSR
Metsera Profile
(
Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Read More
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
